Translational Medicine: Interdisciplinary Biomedical Technologies MSc

Dr Jo Morris and Professor Ben Willcox discuss the benefits of the new Translational Medicine: Interdisciplinary Biomedical Technologies MSc which starts September 2013.

Duration: 02.0 mins

Speaker

S1 -  Dr Jo Morris, Reader in Cancer Genetics, UoB
S2 - Professor Ben Wilcox, Professor of Molecular Immunology

Transcript

S1 Hello, my name’s Jo Morris, I’m a Reader in Cancer Genetics at the University of Birmingham and my particular interest is DNA repair and breast cancer research and I try and combine our understanding of how genes are fixed and put back together with cancer predisposition.

S1 The translational medicine programme is a full time taught MSc. It’s a great opportunity for clinical and non-clinical scientists to get up to speed with the latest in translational medicine. The course will really help you understand how new technologies are being applied to the treatments of major diseases. So this course is going to focus on drug design, the use of bio-markers and some of the [Omex - 0:00:39] technologies – so that’s genetics, transcription analysis and metabolomics – some of the bio-physical sciences that really help us drill down and understand diseases better. 

S1 The best bit about this programme is that you will be doing an independent and original project during the programme.

S2 The lectures will include those from key clinicians who are real field

leaders in their respective areas and that’s across a whole range of different fields – liver disease, cancer, inflammation – but also experts in the respective technology that can be applied to those different areas. We’ve got one of Europe’s biggest teaching hospitals on site and also a fantastic clinical trials set up as well, so we’re in a unique position to think about how to use these new technologies to make major advances in translational medicine. If you’re an overseas student considering this course then one of its major advantages is that it’s one of the few courses in the EU to offer this translational medicine agenda in a one year format.

S1 So if you’re interested in taking this a bit further, please feel free to drop us an email or look at the website address and we really hope to see you in September.

End of recording